Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58024 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL2957009 | 0.98 | CYP3A4 (0.96) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL28209668 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL15419989 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL30814247 | 0.89 | CYP3A4 (0.79) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL453850 | 0.88 | CYP3A4 (0.79) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL453849 | 0.88 | CYP3A4 (0.79) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL4776145 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL22147 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP2C9CES1CES2AKR1B1 | |
| SCHEMBL6432268 | 0.85 | CYP3A4 (0.73) | CYP3A4CYP2C9CES1CES2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | claimed |
| US-6121234-A | ORALLY COADMINISTERING TO MAMMAL PHARMACEUTICAL COMPOUND AND ESSENTIAL OIL | AVMAX, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0831870-A4 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | AVMAX INC (US) | 1998-09-16 | — | — | EP | claimed |
| EP-0831870-A1 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | Avmax, Inc. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5716928-A | ADMINISTERING DRUG CONCURRENTLY WITH ESSENTIAL OIL | AVMAX, INC. (US) | 1998-02-10 | — | — | US | claimed |
| US-5665386-A | Use of essential oils to increase bioavailability of oral pharmaceutical compounds | AVMAX, INC. (US) | 1997-09-09 | — | — | US | claimed |
| WO-1996040192-A1 | USE OF ESSENTIAL OILS TO INCREASE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS | AVMAX, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20140271863-A1 | HOT WASHABLE POLY-N-ISOPROPYLACRYLAMIDE HYDROGEL DELIVERY SYSTEMS | Textile-Based Delivery, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8449863-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8128906-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8128905-B2 | Stabilized uncoated particles of reversed liquid crystalline phase materials | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2364696-A1 | Formulations for delivery via pressurised metered dose inhalers | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2011-09-14 | — | — | EP | disclosed |
| EP-2089008-B1 | FORMULATIONS FOR DELIVERY VIA PRESSURISED METERED DOSE INHALERS COMPRISING AN ESSENTIAL OIL AS SUSPENSION STABILISER | UNIV LONDON PHARMACY (GB) | 2011-07-20 | — | — | EP | disclosed |
| EP-1345589-A4 | SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS | LYOTROPIC THERAPEUTICS INC (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003106382-A2 | REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES | LYOTROPIC THERAPEUTICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-1345589-A1 | SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS | Lyotropic Therapeutics, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030022242-A1 | Particle for use in the absorption of one or more materials in preferential environments | LYOTROPIC THERAPEUTICS, INC. | 2003-01-30 | — | — | US | disclosed |
| WO-2003000236-A1 | PARTICLES WITH IMPROVED SOLUBILIZATION CAPACITY | LYOTROPIC THERAPEUTICS, INC (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020102280-A1 | Solvent systems for pharmaceutical agents | LYOTROPIC THERAPEUTICS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002043696-A1 | SOLVENT SYSTEMS FOR PHARMACEUTICAL AGENTS | LYOTROPIC THERAPEUTICS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |